Financing Enables Cannabinoid Innovator to Continue Phase I-II Trials Of Numerous Intellectual Property (IP) Protected Cannabinoid-Based Products for Multiple Indications SAN DIEGO, CA– AXIM, MJNA, (Marketwired – October 26, 2016) – Medical Marijuana, Inc. (OTC PINK: MJNA) today announced that its portfolio company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, has secured private funding to continue its pharmaceutical clinical trials program in cannabinoid research and development for multiple indications. AXIM® Biotech’s mostRead more
- Research on Lodonal for HIV related GI complications featured in Plus Magazine
- Cannabis Strategic Ventures and Sunniva Inc. Enter Into Cannabis Extraction Services Agreement
- Precision Therapeutics Merger with Helomics Corp. Accelerates Personalized Cancer Treatment Strategies
- Precision Therapeutics Granted European Patent for its Automated, Direct-to-Drain Medical Fluid Disposal System
- PHI Group Partners with Fintech Green Investment Company
SMALL CAP MARKET NEWS
We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.
LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!
Stock Investors · Accredited Investors · Hedge Fund InvestorsLearn More